Skip to main content
TipRanks
Go Ultimate75% OFF

Maravai Lifesciences Holdings (MRVI) Revenue by Segment

426 Followers

Revenue by Segment

In Q3 2026, Maravai Lifesciences Holdings reported revenue by segment of $28.35M (Nucleic Acid Production) and $17.50M (Biologics Safety Testing).

Analyzes revenue contributions from various business segments, indicating which areas are leading growth and where strategic focus might be needed.

$0.00$50.00M$100.00M$150.00M$200.00M$250.00MMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26Sep 26
Chart Insights

Nucleic Acid Production (TriLink) has normalized well below the COVID peak but is showing renewed 2026 momentum as the business shifts to higher‑margin GMP and discovery mRNA sales—aligning with management’s high‑teens TriLink growth and large CleanCap/GMP orders—while Biologics Safety Testing (Cygnus) delivers steady, low‑single‑digit growth with strong margins. Protein Detection has effectively been de‑emphasized/exited. The mix shift supports the margin expansion and EBITDA guidance but keeps near‑term results exposed to lumpy, program‑timed GMP/CDMO orders until new GMP products scale in 2027.

MRVI Revenue by Segment

PeriodNucleic Acid ProductionBiologics Safety TestingProtein Detection
Q3 2026Sep 30, 2026$28.35M$17.50M$0.00
Q2 2026Jun 30, 2026$34.67M$16.77M$0.00
Q1 2026Mar 31, 2026$47.48M$18.36M$0.00
Q4 2025Dec 31, 2025$34.60M$15.27M$0.00
Q3 2025Sep 30, 2025$25.35M$16.28M$0.00
Q2 2025Jun 30, 2025$31.09M$16.31M$0.00
Q1 2025Mar 31, 2025$28.75M$18.10M$0.00
Q4 2024Dec 31, 2024$41.90M$14.66M$0.00
Q3 2024Sep 30, 2024$53.84M$15.18M$0.00
Q2 2024Jun 30, 2024$58.48M$14.92M$0.00
Q1 2024Mar 31, 2024$46.02M$18.16M$0.00
Q4 2023Dec 31, 2023$58.83M$15.32M$0.00
Q3 2023Sep 30, 2023$51.23M$15.64M$0.00
Q2 2023Jun 30, 2023$53.27M$15.65M$0.00
Q1 2023Mar 31, 2023$61.45M$17.57M$0.00
Q4 2022Dec 31, 2022$189.29M$15.42M$0.00
Q3 2022Sep 30, 2022$174.88M$16.38M$0.00
Q2 2022Jun 30, 2022$225.25M$17.48M$0.00
Q1 2022Mar 31, 2022$223.65M$20.64M$0.00
Q4 2021Dec 31, 2021$212.51M$15.93M$0.00
Q3 2021Sep 30, 2021$182.90M$16.63M$5.28M
Q2 2021Jun 30, 2021$192.74M$18.21M$7.05M
Q1 2021Mar 31, 2021$124.17M$17.65M$6.63M
Q4 2020Dec 31, 2020$77.75M$14.13M$6.48M
Q3 2020Sep 30, 2020$67.66M$14.11M$6.09M
Q2 2020Jun 30, 2020$30.42M$12.36M$4.12M
Q1 2020Mar 31, 2020$30.49M$14.29M$6.20M

Related KPIs